The Expression Of TCERG1L In Breast Ductal Carcinoma In Situ, Invasive Ductal Carcinoma And Its Correlation With Clinicopathological Parameters

Background and Purpose:Breast cancer is the most frequent malignancy of women worldwide, and themain cause of cancer deaths in women. Transcription elongation regulator1-like(TCERG1L) is a nuclear protein, and have a function for regulating the DNAtranscription and splicing the pre-mRNA. So far, the correlation between TCERG1Land human Disease had achieved certain results. In recent GWAS studies, variants atTCERG1L have been associated with insulin resistance and attention deficit disorder,and TCERG1L is associated with plasma adiponectin(a key modulator of obesity,inflammation, IR and diabetes); Hypermethylation of the TCERG1L promoter regionhas also been observed in ulcerative colitis and colon cancer. But the correlationbetween TCERG1L and breast cancer remained unclear. This paper aims toinvestigate the expression of TCERG1L in invasive ductal carcinoma and ductalcarcinoma in situ，and analysis its relationship with clinical pathological parameters.Methods:1、By IHC, we detected the expression of TCERG1L in30cases of benigntissues，29cases of ductal carcinoma in situ，33cases of invasive ductal carcinomaand33cases of adjacent normal tissues.2、Meanwhile,We also detected the expression of TCERG1L in normal breastepithelial cell line（HBL-100cell line）、breast cancer cell line（MCF-7cell line、MDA-MB-231cell line）via western blot.Results:1、The results of IHC about the expression of TCERG1L in breast benigntissues，ductal carcinoma in situ, invasive ductal carcinoma and adjacent normaltissue:The positive expression of TCERG1L localized in the nucleus. The expression ofTCERG1L in benign lesions and adjacent normal tissue was significantly higher than that in DCIS and IDC (P<0.01),The positive expression rate were respectively93.3%(28/30)，100%(33/33)，79.3%(23/29)，63.6%(21/33). Between benign lesionsand adjacent normal tissue group, the differences appeared no significant (P>0.05).Between DCIS and IDC group, the differences also appeared no significant (P>0.05).In addition, in21cases of DCIS+IDC, there are20cases of consistent expression ofTCERG1L.2、The relationship between the expression of TCERG1L and clinicalpathological parameters in breast invasive ductal carcinoma:The expression of TCERG1L is negatively related with ER、PR(respectivelyr=-401，P<0.05；r=-0.488，P<0.05); while in each group of age, CerbB-2, metastasisof lymph node, tumor size and Clinical stage, the difference of the expression ofTCERG1L appeared no significant（P>0.05）.3、The results of Western Blot about the expression of TCERG1L in normalbreast epithelial cell line（HBL-100cell line）、breast cancer cell line（MCF-7cellline、MDA-MB-231cell line）:TCERG1L was highly expressed in HBL-100cell line and MDA-MB-231celllines, while it showed low expression in MCF-7cell lines. The expression ofTCERG1L in HBL-100cell line appeared significantly higher in MCF-7cell line（P<0.01）. But between in HBL-100cell line and MDA-MB-231cell lines, it did notshow significant differences.Conclusion:1、The expression of TCERG1L in DCIS and IDC was lower than that inbenign lesions and adjacent normal tissue.2、The expression of TCERG1L appeared negatively related with ER、PR inbreast invasive ductal carcinoma.3、TCERG1L was highly expressed in MDA-MB-231cell lines(ER-、PR-), whileit showed low expression in MCF-7cell lines(ER+、PR+). The low expression ofTCERG1L in breast cancer cell lines may be associated with the positive expression of ER and PR.